On September
11, 2020, Bioworkshops held our first Enterprise Open Day, attended by
government leaders and industry experts from the pharmaceutical industry. The Open Day gave opportunity to share the
important role of CDMO enterprises in the growth of the biological medicine
industry. Bioworkshops 's expert team also introduced the guests to how
Bioworkshops quickly satisfied customers’ requirements, accelerating the
development process of biological medicines.
As an
enterprise supported by Suzhou Industrial Park, Bioworkshops has taken root in
the Industrial Park and grown rapidly. Leaders from the China-Singapore Suzhou
Industrial Park Development Group, the Science and Education Innovation Zone,
the Science and Technology and Information Technology Bureau, and the Market
Supervision and Administration Bureau attended the event. Liu Hua, Member of
the Party Working Committee of Suzhou Industrial Park and Deputy Director of
the Management Committee, also attend the enterprise Open Day. She said “Suzhou
Industrial Park has implemented innovation-driven development strategy in
recent years. It has made great effort to build a world-class biomedical
industry and become one of the most competitive domestically-developed
biomedical parks. In less than a year Bioworkshops has already completed the
development and construction of development laboratories and put them to use.
At the same time, Bioworkshops completed construction of the production
workshops for six 2,000L bioreactors, which clearly shows both
scientific-oriented ‘innovation strength’ and ‘practical speed’. We sincerely congratulate Bioworkshops on
their early achievements and hope that it will continue this momentum into the
future, seize the development opportunities to grow, to empower, and to
energize the city.”
Dr. Nick
Kotlarski, COO of Bioworkshops said in his address, "We are honored to
host government leaders to witnessed the rapid growth of Bioworkshops, as well
as the biopharmaceutical industry experts who have supported and collaborated
with our company. Proactive national
policy and the booming biologics industry has encouraged CDMOs to set up in
recent years. We provide the industry 'craftsman' to cooperate with domestic
research and development companies and help overtake the curve relative to
competitors. Flexible and efficient design and clear communication to complete
fast delivery is our consistent style of execution. Quality first, and
value-creation for our clients and their patients is the service philosophy of
Bioworkshops. The Enterprise Open Day is an opportunity for us to let more
industry experts know about Bioworkshops."
Dr. Nick
Kotlarski emphasized that "Bioworkshops provides one-stop comprehensive
services from construction of stable cell line, through process development,
cGMP manufacture for clinical research, to commercial production. We took only
eight months to build cGMP facilities and full supporting services. Now we provide services to established
biopharmaceutical companies with our cGMP manufacturing capacity and also
continue to empower emerging biopharmaceutical enterprises, to accelerate the
development of innovative drugs, with our own platform advantages." Dr.
Kotlarski has been working in China for many years and witnessed the dramatic
development of the Chinese biopharmaceutical industry first-hand. The rapid
development and early success of Bioworkshops proves that CDMO play an
important role to enable breakthroughs in the fierce competition within the
healthcare industry and drive the industry towards a better state.
As part of
the Open Day, the guests visited the R&D and production workshops.
Bioworkshops’ scientists explained the layout of the workshops, functional
divisions, equipment capacity, and plant operation process in detail. The
founding team of Bioworkshops has rich experience in design, construction and
operation of biopharmaceutical facilities, having set up four biological
medicine research and development centers and production workshops in the past
five years. The result of this experience is evident in the overall plant
design, layout, and construction of the Bioworkshops quality system to reduce
customer costs and improve the efficiency of biological medicine research and
development. Two 200L-500L tandem disposable bioreactor production lines have
been put into operation, the 2×2000L production line will be launched in Q3,
and the addition of another four 2000L production reactors is earmarked for
2021.
The Bioworkshops team has deep experience in research and development from more than 40 biological drug products, and has full understanding and practical experience of FDA and EMA drug approval processes. At present, Bioworkshops has six CMC development projects in progress. Providing quality-first, customer-oriented services, Bioworkshops will help drive the rapid development of the industry and continue to demonstrate "Bioworkshops Speed" into the future.